维普中文期刊产品整合服务
10篇 您的检索式:作者名="Burbridge MF"
    题名 作者 年代 出处 被引量
149076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab 显示文摘BURBRIDGE MF BOSSARD C J SAUNIER C 2013Mol Cancer Ther2013,12,9:1
2S49076 is a novel kinase inhibitor of MET,AXL,and FGFR with strong preclinical activ-ity alone and in association with bevaci- zumab显示文摘Burbridge MF Bossard CJ Saunier C 2013Mol Cancer Ther2013,12,:1
3hnproved quantification of angiogenesis in the rat aortic ring assay显示文摘Blacher S Devy L Burbridge MF 2001Angiogenesis2001,4,2:1
4The role of the matrix metalloproteinases during in vitro vessel formation显示文摘Burbridge MF Coge F Galizzi JP 2002Angiogenesis2002,5,3:1
5S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab显示文摘Burbridge MF Bossard CJ Saunier C 2013Mol Cancer Ther2013,12,9:1
6Improved quantification of angiogenesis显示文摘Blacher S Devy L Burbridge MF 1995Lab Invest1995,75,5:1
7Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice:use of the CA125 tumour marker to predict antitumour activity显示文摘Burbridge MF Kraus-Berthier L Naze M 1999Int J Oncol1999,15,6:1
8Improved quantification of angiogenesis in the rat aortic ring assay 显示文摘Blather S Devy L Burbridge MF 2001Angiogene sis2001,4,2:1
9The role of the-matrix metalloproteinases during in vitro vessel formation显示文摘Burbridge MF CogéF Galizzi JP 2002Angiogenesis2002,5,3:1
10S49076 is a novel kinase inhibitor of Met, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab显示文摘Burbridge MF Bossard CJ Saunier C 2013Mol Cancer Ther2013,12,9:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费